Genmab AS (GMAB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Genmab AS stock (GMAB) is currently trading at $26.11. Genmab AS PE ratio is 16.76. Genmab AS PS ratio (Price-to-Sales) is 4.28. Analyst consensus price target for GMAB is $37.65. WallStSmart rates GMAB as Underperform.
- GMAB PE ratio analysis and historical PE chart
- GMAB PS ratio (Price-to-Sales) history and trend
- GMAB intrinsic value — DCF, Graham Number, EPV models
- GMAB stock price prediction 2025 2026 2027 2028 2029 2030
- GMAB fair value vs current price
- GMAB insider transactions and insider buying
- Is GMAB undervalued or overvalued?
- Genmab AS financial analysis — revenue, earnings, cash flow
- GMAB Piotroski F-Score and Altman Z-Score
- GMAB analyst price target and Smart Rating
Genmab AS
📊 No data available
Try selecting a different time range
GMAB Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Genmab AS (GMAB)
GMAB trades 187% above its Graham fair value of $10.47, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Genmab AS (GMAB) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, profit margin. Concerns around revenue growth and eps growth. Fundamentals are solid but monitor weak areas for improvement.
Genmab AS (GMAB) Key Strengths (4)
Keeps $26 of every $100 in revenue as net profit
Large-cap company with substantial market presence
Strong operational efficiency: $23 kept per $100 revenue
Solid profitability: $18 profit per $100 equity
Supporting Valuation Data
Genmab AS (GMAB) Areas to Watch (6)
Earnings declining -94.40%, profits shrinking
Revenue growing slowly at 3.00% annually
Very low institutional interest at 12.13%
Premium valuation at 4.3x annual revenue
Growth is fairly priced, not cheap, not expensive
Fairly priced relative to book value
Genmab AS (GMAB) Detailed Analysis Report
Overall Assessment
This company scores 54/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.5/10) while 6 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Profit Margin, Market Cap, Operating Margin. Profitability is solid with Return on Equity at 17.50%, Operating Margin at 23.00%, Profit Margin at 25.90%.
The Bear Case
The primary concerns are EPS Growth, Revenue Growth, Institutional Own.. Some valuation metrics including PEG Ratio (1.62), Price/Sales (4.28), Price/Book (2.64) suggest expensive pricing. Growth concerns include Revenue Growth at 3.00%, EPS Growth at -94.40%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 17.50% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 3.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Profit Margin, Market Cap) and negatives (EPS Growth, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GMAB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GMAB's Price-to-Sales ratio of 4.28x trades at a deep discount to its historical average of 10.57x (53th percentile). The current valuation is 91% below its historical high of 49.92x set in Nov 2015, and 449% above its historical low of 0.78x in Jul 2025. Over the past 12 months, the PS ratio has expanded from ~1.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Genmab AS (GMAB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Genmab AS is a strong growth company balancing expansion with improving profitability. Revenue reached 3.7B with 300% growth year-over-year. Profit margins are strong at 25.9%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 300% YoY, reaching 3.7B. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 1750.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Earnings fell 94% YoY while revenue grew 300%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can Genmab AS maintain 300%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Genmab AS.
Bottom Line
Genmab AS offers an attractive blend of growth (300% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Genmab AS(GMAB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.